Quantcast

Latest Typical antipsychotic Stories

2011-09-27 18:07:21

Medical evidence suggests that psychiatric drugs known as atypical antipsychotics are effective in reducing symptoms for some off-label conditions, but not others, according to a new RAND Corporation study. Evidence supports the effectiveness of some atypical antipsychotics in reducing symptoms of generalized anxiety disorder, obsessive-compulsive disorder, post-traumatic stress disorder and behavioral symptoms in elderly patients with dementia, although significant side effects were...

2011-04-11 07:00:00

TITUSVILLE, N.J., April 11, 2011 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) on April 6 approved INVEGA® (paliperidone) extended-release tablets for the treatment of schizophrenia in adolescents 12 to 17 years of age. The efficacy of INVEGA® to treat schizophrenia in adolescents was established in one six-week clinical study. INVEGA® is an atypical antipsychotic medication and was first approved in the U.S. in December...

2011-04-04 15:46:00

BEERSE, Belgium, April 4, 2011 /PRNewswire/ -- Janssen EMEA -- New data from an independent prospective study presented last week at the 19th European Congress of Psychiatry (EPA 2011) shows treatment with Risperdal® Consta® (risperidone long-acting injection (RLAI)) is associated with a lower risk of hospitalisation in patients with schizophrenia compared to treatment with other antipsychotics over a 12-month period. The data was collected as part of the...

2011-03-28 21:44:44

Conventional antipsychotics, antidepressants and benzodiazepines often administered to nursing home residents are no safer than atypical antipsychotics and may carry increased risks, according to an article in CMAJ (Canadian Medical Association Journal) (pre-embargo link only) http://www.cmaj.ca/embargo/cmaj101406.pdf. Psychotropic medications are often used to manage behavioral symptoms in seniors, particularly people with dementing illnesses, with up to two-thirds of dementia patients in...

2011-02-07 21:50:30

A warning issued by the Food and Drug Administration regarding the use of atypical antipsychotics for the treatment of dementia was associated with a significant decline in the use of these medications for treating dementia symptoms in elderly patients, according to a report in the February issue of Archives of General Psychiatry, one of the JAMA/Archives journals. "In 2001, more than 70 percent of U.S. atypical antipsychotic prescriptions were written for off-label indications such as...

692a477b154ab04597e11f21e9246bcb
2011-01-07 08:45:00

Researchers from the Stanford University School of Medicine and the University of Chicago have found that many people currently using a specific type of antipsychotic medication are doing so for a condition that the drug has not yet been proven effective in treating. According to their findings, published online Friday in the journal Pharmacoepidemiology and Drug Safety, atypical antipsychotic medications were originally approved by the Food and Drug Administration (FDA) in 1989 for treating...

2010-08-24 07:00:00

LOUISVILLE, Ky. and FRANKLIN LAKES, N.J., Aug. 24 /PRNewswire/ -- SureGene, LLC and the Medco Research Institute(TM), LLC, a wholly-owned subsidiary of Medco Health Solutions, Inc. (NYSE: MHS), today announced that they have entered into a novel investigative research collaboration to evaluate whether variation in genetic biomarkers previously identified by SureGene can help predict drug response for widely prescribed antipsychotic drugs in patients with serious mental illness. The results...

2010-08-05 12:00:00

WALTHAM, Mass., Aug. 5 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, after peaking at $6.3 billion in 2011, the schizophrenia drug market will decline to $5.2 billion in 2019, owing to the loss of patent protection for most atypical antipsychotics on the market. The Pharmacor 2010 findings from the topic entitled Schizophrenia reveal that the generic erosion of key agents -- most notably...

2010-05-21 07:00:00

TITUSVILLE, N.J., May 21 /PRNewswire/ -- New data on INVEGA® SUSTENNA® (paliperidone palmitate), a long-acting injectable medicine for schizophrenia, and new data on RISPERDAL® CONSTA® (risperidone long-acting therapy), also an injectable medicine to treat schizophrenia, will be presented next week at a major psychiatry meeting in New Orleans. Posters on this data will be presented on Wednesday, May 26, from 12 noon to...


Word of the Day
bodacious
  • Remarkable; prodigious.
  • Audacious; gutsy.
  • Completely; extremely.
  • Audaciously; boldly.
  • Impressively great in size; enormous; extraordinary.
This word is probably from the dialectal 'boldacious,' a blend of 'bold' and 'audacious.'
Related